Masso Torrence Wealth Management Inc. Has $160,000 Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Masso Torrence Wealth Management Inc. increased its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 200.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,000 shares of the company’s stock after buying an additional 20,000 shares during the quarter. Masso Torrence Wealth Management Inc.’s holdings in Corvus Pharmaceuticals were worth $160,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in CRVS. Point72 Asset Management L.P. acquired a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter worth approximately $10,855,000. Geode Capital Management LLC lifted its stake in Corvus Pharmaceuticals by 22.4% during the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock worth $2,974,000 after purchasing an additional 102,869 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter valued at $136,000. State Street Corp increased its stake in shares of Corvus Pharmaceuticals by 48.2% in the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock valued at $941,000 after purchasing an additional 57,943 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Corvus Pharmaceuticals by 64.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after buying an additional 53,809 shares in the last quarter. Institutional investors and hedge funds own 46.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Oppenheimer increased their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th. Finally, StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $12.38.

Corvus Pharmaceuticals Trading Up 1.6 %

Corvus Pharmaceuticals stock opened at $5.15 on Wednesday. The firm’s fifty day moving average price is $6.47 and its two-hundred day moving average price is $5.75. The firm has a market capitalization of $330.94 million, a price-to-earnings ratio of -5.54 and a beta of 1.07. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $10.00.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.